Case Study: PLGA Microsphere Formulation Development for a 3-Month Depot Antipsychotic

Introduction:

PLGA microsphere formulation development is one of the most technically demanding disciplines in long-acting injectable (LAI) drug delivery, and nowhere is this more evident than in 3-month depot antipsychotics. Extending release from the more common 4-week interval out to 90 days is not simply a matter of using “more” or “slower” polymer. It requires the polymer matrix, particle architecture, drug distribution within the sphere, sterilization method, and manufacturing process to all move in the same direction at once — and there is very little room for error, because a formulation that releases too fast risks subtherapeutic troughs and relapse, while one that releases too slowly risks accumulation and toxicity over repeated dosing cycles.

This case study describes how a formulation and analytical team approached PLGA microsphere formulation development for a 3-month depot antipsychotic candidate: the reasoning behind polymer selection, the process problems that came up during scale-up, the analytical data that guided each decision, the sterilization and stability strategy, and the final performance profile that supported progression toward IND-enabling work. PLGA (polylactic-co-glycolic acid) for parenteral use has decades of regulatory precedent behind it, but that track record doesn’t remove the need for rigorous, project-specific development work. The intent here is to give formulators, CMC teams, and program leads a realistic view of what this kind of development actually involves, rather than a simplified summary.

Depot antipsychotics have become a cornerstone of relapse-prevention strategy in schizophrenia and related disorders because they remove the day-to-day burden of oral adherence, and PLGA’s role in CNS drug delivery across the blood-brain barrier makes it a natural fit for this therapeutic class specifically. A patient who might miss doses on an oral regimen can instead receive a single injection every 4, 8, or 12 weeks. Marketed products such as risperidone microspheres illustrate how reverse engineering risperidone PLGA microspheres has informed the broader antipsychotic depot category, but the clinical benefit of a 3-month interval only exists if the underlying PLGA microsphere formulation development program gets the release kinetics right — and that is where the bulk of the technical risk in these programs actually sits.

Summary:

• PLGA microsphere formulation development for a 3-month long-acting injectable (LAI) antipsychotic requires precise, interdependent control of polymer chemistry, particle architecture, and manufacturing process — not just a single “right” polymer grade.
• This case study walks through a representative ResolveMass project end-to-end: polymer screening and blending strategy, solvent-evaporation process optimization, encapsulation efficiency troubleshooting, particle size control, sterilization, stability, and in vitro release (IVR) method design.
• Key formulation levers include PLGA lactide:glycolide ratio, molecular weight, end-group chemistry (acid vs. ester), internal/external phase ratio, and stirring dynamics during emulsification.
• The analytical strategy combined GPC/SEC, laser diffraction, HPLC/UPLC, DSC, SEM, and residual solvent testing, run in parallel across the development timeline rather than as an afterthought.
• The final formulation achieved a near-zero-order release profile over 90 days, encapsulation efficiency above 85%, and batch-to-batch consistency suitable for supporting IND-enabling studies.
• Regulatory expectations for PLGA depot antipsychotics — particularly around IVIVC, sterility assurance, and comparability — are outlined alongside where this program’s data package aligned with FDA and EMA guidance for complex, non-biological complex drug (NBCD) injectables.

1: Why Is PLGA the Polymer of Choice for Long-Acting Antipsychotics?

PLGA (poly lactic-co-glycolic acid) is preferred because it is biodegradable, biocompatible, and its degradation rate can be tuned by adjusting the lactide-to-glycolide ratio, molecular weight, and end-group chemistry. This tunability is precisely what makes 90-day release achievable, since no single “off the shelf” PLGA grade is typically sufficient — most 3-month depot programs rely on blends or custom compositions.

The role of PLGA polymer grade in long-acting release formulation cannot be overstated — grade selection is arguably the single highest-leverage decision in the entire program. Three structural variables drive degradation and release rate:

• Lactide:glycolide ratio — Lactide is more hydrophobic than glycolide, so higher lactide content slows water uptake and hydrolysis, extending degradation time. A 50:50 ratio degrades faster than a 75:25 or 85:15 ratio, a relationship explored further in this comparison of PLGA, PLA, and PCL degradation rates.
• Molecular weight — Higher molecular weight polymers have longer chains that take more hydrolytic cleavage events to break down into soluble oligomers, which extends the erosion phase.
• End-group chemistry — Acid-terminated (uncapped) PLGA has a free carboxylic acid end group that autocatalyzes hydrolysis, accelerating degradation. Ester-terminated (capped) PLGA degrades more slowly because it lacks this autocatalytic effect. The polymer’s glass transition temperature is also closely tied to end-group chemistry and molecular weight, and needs to be characterized alongside degradation behavior rather than in isolation.

Several PLGA grades were screened in this project:

For a 3-month target, a single-grade approach proved insufficient during early screening — RG 503 alone produced release that tailed off before Day 90 in a meaningful fraction of the dose, while RG 752S alone extended release too far past the target window. The resolution was a blended-polymer approach, combining a majority fraction of a 50:50 ester-capped polymer with a smaller fraction of 75:25 polymer, allowing the erosion window to be fine-tuned without over- or under-shooting the intended 90-day release target. Working with a supplier that can provide detailed lot-specific characterization data is one of the practical benefits of a qualified PLGA supplier that becomes especially valuable when a blending strategy is required.

2: How Does PLGA Microsphere Technology Compare to Other Long-Acting Injectable Platforms?

PLGA microspheres are one of several long-acting injectable drug delivery technologies, and they were selected for this program over alternative platforms because they offer the most established regulatory precedent and the widest control range for extending release out to 90 days. Understanding where microspheres sit relative to other approaches helps explain why this platform, rather than an alternative, was chosen at the outset — including how they differ from PLGA nanoparticles, which operate on a different size scale and release mechanism entirely, and from the characterization approaches used for long-acting biologics, which involve additional considerations around protein stability that small-molecule antipsychotics do not face.

PLGA microspheres were the platform of choice for this program specifically because the 90-day target falls within the range where the polymer’s degradation behavior is well characterized and predictable, and because microsphere suspensions can be delivered through a standard 20–22 gauge needle, unlike the larger-bore devices often required for PLGA oncology implants. PLGA’s versatility extends well beyond systemic depot injections, too — the same polymer platform underpins PLGA-based ocular drug delivery and PLGA for pulmonary drug delivery, though each route brings its own particle size and release-rate requirements that differ from a subcutaneous or intramuscular depot.

3: What Manufacturing Process Was Used to Build the Microspheres?

The microspheres were produced using an oil-in-water (O/W) single-emulsion solvent evaporation process, selected for its scalability, its established regulatory precedent for marketed PLGA depot products, and its compatibility with the antipsychotic’s moderate lipophilicity. Every step of this process was executed against the applicable GMP requirements for PLGA manufacturing, since process deviations at this stage translate directly into batch-to-batch release variability later. The API and PLGA blend were dissolved together in dichloromethane (the organic/internal phase), emulsified into an aqueous polyvinyl alcohol (PVA) solution (the external phase), and hardened under controlled agitation as the organic solvent evaporated out of the droplets, leaving solid drug-loaded microspheres suspended in the aqueous phase.

Process Parameters and Their Effect on Particle Characteristics

Small adjustments to stirring speed alone shifted the mean particle size from roughly 40 µm to over 90 µm across trial batches, which is a meaningful demonstration of how sensitive PLGA microsphere formulation development is to process control and not just formulation composition. Because particle size directly affects both the surface-area-to-volume ratio (and therefore burst release) and the injectability of the final suspension through a 20–22 gauge needle, this parameter was treated as a critical process parameter (CPP) and locked early, ahead of finalizing the polymer blend ratio.

Scale-Up Considerations

Moving from a 1 L bench-scale batch to a pilot-scale 10 L batch introduced predictable but manageable shifts in particle size distribution, primarily due to changes in local shear profiles within a larger vessel. Impeller geometry, batch volume, and mixing time were re-optimized at each scale, with particle size distribution (D10/D50/D90) used as the primary bridging metric between scales rather than relying on stirring speed (RPM) alone, since RPM does not translate directly across vessel geometries. This is precisely the kind of bridging work covered by dedicated PLGA microsphere scale-up services, where analytical comparability data — not just process parameters — is used to justify that a scaled batch behaves equivalently to its bench-scale predecessor.

4: How Was the Product Sterilized Without Compromising the Polymer or Release Profile?

Terminal moist-heat sterilization (autoclaving) was ruled out early because PLGA has a glass transition temperature well below standard autoclave cycles, meaning the microspheres would deform, aggregate, or prematurely accelerate degradation under that level of heat exposure. Aseptic processing was used instead, with sterile filtration of the API and excipient solutions upstream of the emulsification step and the full microsphere manufacturing process conducted under Grade A/B cleanroom conditions.

Two sterilization-adjacent risks were specifically evaluated during development:

• Gamma irradiation was assessed as an alternative but was found to reduce PLGA molecular weight through radiation-induced chain scission, which shortened the release duration in side-by-side comparisons against non-irradiated batches — making it unsuitable for a 90-day target without significant reformulation to compensate.
• Bioburden control during aseptic processing was managed through sterile-filtered raw materials, validated aseptic transfer steps, and environmental monitoring throughout the emulsification and hardening stages, since the finished microsphere suspension cannot be sterile-filtered once particles have formed.

This sterilization strategy is consistent with the approach used across most marketed PLGA depot products, where aseptic manufacture — rather than terminal sterilization — is standard practice specifically because of PLGA’s thermal and radiation sensitivity. The same sensitivity is a major consideration in PLGA-based peptide delivery programs, where both heat and radiation exposure can degrade the peptide payload in addition to the polymer itself.

5: How Was Drug Loading and Encapsulation Efficiency Optimized?

Encapsulation efficiency was optimized by matching API solubility behavior to the emulsion system and minimizing drug migration into the aqueous phase during hardening. This challenge tends to be even more pronounced in programs formulating highly potent APIs using PLGA microspheres, where even small losses in encapsulation efficiency carry outsized dosing consequences. Early batches showed encapsulation efficiency below 65%, which was traced back to partial API solubility in the PVA solution — as the organic solvent evaporated, a portion of the API diffused out of the hardening droplet and into the surrounding aqueous phase before the polymer shell fully solidified, effectively becoming process waste rather than encapsulated drug. High-drug-load formulations face a related set of challenges, as documented in a separate buprenorphine depot PLGA characterization case study examining high-drug-load systems.

Root Cause and Corrective Actions

1. Aqueous-phase saturation — The PVA solution was pre-saturated with a small, controlled amount of the API itself, which reduced the concentration gradient driving diffusion out of the forming particle.
2. pH adjustment — The pH of the aqueous phase was adjusted to reduce API ionization, since the ionized form of the molecule was substantially more water-soluble than the neutral form, and ionization state turned out to be a larger driver of drug loss than initially assumed.
3. Accelerated solvent removal — Solvent evaporation time was shortened using controlled vacuum assistance, locking the API into the solidifying polymer matrix before diffusion into the aqueous phase could occur to a significant degree.
4. Phase ratio adjustment — The organic-to-aqueous volume ratio was narrowed slightly, reducing the total aqueous “sink” available for API to migrate into.

These four changes, applied together rather than individually, raised encapsulation efficiency from below 65% to consistently above 85%, with a corresponding drop in batch-to-batch variability in both drug loading and release rate. This combination of process changes — rather than any single fix — is a useful illustration of how encapsulation efficiency problems in PLGA microsphere formulation development are rarely solved by adjusting one variable in isolation.

6: How Was the 90-Day Release Profile Confirmed?

The 90-day release profile was confirmed using a dual-track in vitro release (IVR) testing strategy: real-time testing under physiological conditions alongside an accelerated method used for earlier, faster read-outs during formulation screening. Real-time testing ran the full 90-day course at 37°C in isotonic buffer under gentle agitation, while the accelerated method used elevated temperature to compress the erosion timeline, giving the team preliminary release data in roughly 2–3 weeks instead of waiting the full 90 days for every screening decision.

The confirmed release profile showed three characteristic phases common to PLGA depot systems:

• Initial burst (Days 0–3): A controlled, limited release from drug located near or at the particle surface, driven primarily by diffusion rather than polymer erosion. Excessive burst release in PLGA formulations was one of the earliest problems identified in this program and was reduced through the porosity-related process changes described above.
• Lag phase (Days 3–30): Minimal drug release while the PLGA matrix undergoes bulk hydrolytic degradation without yet forming enough internal channels for significant drug transport. Molecular weight declines steadily during this window even though little drug is actually released, and the distinction between bulk erosion and surface erosion in PLGA explains why this lag phase exists at all — PLGA is a bulk-eroding polymer, so degradation happens throughout the particle before it becomes visible as drug release.
• Erosion-controlled release (Days 30–90): Near-zero-order release as the PLGA backbone erodes, internal porosity increases, and channels open throughout the matrix, allowing the remaining encapsulated drug to diffuse out at a comparatively steady rate through to Day 90. This later-stage erosion also generates the acidic microenvironment associated with PLGA degradation, a factor that was monitored for potential impact on API stability throughout the release window.

Accelerated vs. Real-Time IVR Correlation

A key validation step was confirming that trends observed in the accelerated method actually predicted real-time outcomes, rather than simply producing faster — but misleading — data. Batches ranked by relative release rate in the accelerated method preserved the same rank order in real-time testing, which supported using the accelerated method for early-stage formulation screening while reserving full real-time IVR testing for confirmatory runs on lead candidates.

Building Toward an In Vitro–In Vivo Correlation (IVIVC)

While full IVIVC development typically requires clinical PK data that falls outside a formulation development program’s early scope, the IVR dataset generated here was structured specifically to support a future Level A correlation — meaning individual in vitro time points could later be mapped directly against plasma concentration time points once preclinical or clinical PK data became available. This forward-looking approach matters because regulatory agencies increasingly expect PLGA depot sponsors to demonstrate a mechanistic link between in vitro release testing and expected in vivo performance, rather than relying on IVR data in isolation.

7: What Stability Data Was Generated, and What Storage Conditions Were Required?

Stability testing followed ICH-aligned long-term and accelerated conditions, with particular attention to two PLGA-specific risks: continued polymer degradation during storage (rather than only after injection) and moisture-driven changes to the microsphere suspension vehicle. General expectations around shelf life for PLGA, PLA, and PCL formed the starting framework for the stability protocol, which was then tailored to this specific polymer blend and dosage form. Samples were pulled at defined intervals and evaluated for molecular weight (GPC/SEC), particle size, encapsulation efficiency, and related substances by HPLC.

Two findings shaped the final storage recommendation:

• Refrigerated storage (2–8°C) measurably slowed polymer molecular weight decline compared to room-temperature storage, extending shelf life and supporting a cold-chain storage recommendation consistent with most marketed PLGA depot antipsychotics.
• Reconstitution timing for the lyophilized/dry microsphere format was found to be a meaningful variable — extended hold times after reconstitution, before injection, allowed measurable early hydration and onset of burst-related drug loss, which supported a defined in-use stability window in the product’s handling instructions.

8: What Analytical Methods Supported This PLGA Microsphere Formulation Development Program?

A multi-technique analytical package was essential to characterizing both the polymer and the finished microspheres at every stage of development, since no single method could explain both what the formulation was doing and why. A broader overview of these approaches is available in this guide to PLGA characterization methods and this companion resource on characterization methods for PLGA microspheres specifically. The core methods used in this program were:

• GPC/SEC (gel permeation/size exclusion chromatography) — Monitored PLGA molecular weight and molecular weight distribution, both as received from the supplier and after accelerated degradation studies, confirming that the polymer’s molecular weight decline over time matched the expected erosion mechanism.
• Laser diffraction particle sizing — Characterized particle size distribution (D10, D50, D90) at every batch to ensure consistency and to correlate particle size directly with observed release rate and burst magnitude.
• HPLC/UPLC — Quantified drug loading, encapsulation efficiency, and released API concentration at each IVR sampling time point, forming the backbone of the release-profile dataset.
• Differential scanning calorimetry (DSC) — Confirmed the glass transition temperature (Tg) of the PLGA matrix, which needed to remain above body temperature at the time of injection to preserve particle integrity, and screened for any API-polymer interactions or unexpected crystallinity.
• Scanning electron microscopy (SEM) — Assessed surface morphology and internal porosity at multiple degradation time points, visually confirming the transition from a relatively smooth, non-porous surface at Day 0 to a progressively eroded, channeled structure by Day 60–90.
• Residual solvent testing (GC headspace) — Confirmed dichloromethane levels in the finished microspheres fell within acceptable limits, since incomplete solvent removal can both pose a safety concern and alter release kinetics. This is one of several areas covered under residual solvent control in PLGA microsphere manufacturing, where process-stage controls matter as much as the final release test.
• Karl Fischer titration — Monitored residual moisture content in the lyophilized product, since elevated moisture can accelerate PLGA hydrolysis during storage.

Together, these methods gave the formulation team a connected dataset linking polymer chemistry, particle architecture, and functional release performance — the kind of integrated evidence package regulators expect to see supporting a long-acting injectable submission, and the kind that is difficult to assemble without analytical and formulation expertise working in close coordination rather than as separate, sequential workstreams.

9: What Do Regulators Expect From a PLGA Depot Antipsychotic CMC Package?

Regulators evaluate PLGA microsphere depot products as complex drug-device-like systems where the manufacturing process itself defines critical quality attributes, meaning CMC packages need to demonstrate process understanding at a level beyond what a simple oral solid dosage form would require, alongside the broader PLGA biocompatibility, safety, toxicology, and regulatory considerations that apply to any PLGA-based product. Both FDA and EMA guidance for long-acting parenteral products emphasize a few recurring themes relevant to this case study:

• Particle size distribution control, since it directly affects both release kinetics and injectability/syringeability
• Demonstrated control over residual solvents and sterility assurance, given that terminal sterilization is generally not feasible for PLGA microspheres
• A scientifically justified IVR method, ideally with a documented path toward IVIVC, rather than an IVR method chosen only for convenience
• Comparability protocols for any process or scale changes, since PLGA microsphere manufacturing is highly sensitive to process parameters that can shift release performance even when the formulation composition itself is unchanged

Programs that generate this kind of interconnected polymer/process/analytical dataset from early development — rather than retrofitting it after formulation lock — are generally better positioned heading into IND-enabling and later regulatory interactions, since much of the required CMC narrative is already supported by existing data rather than needing to be reconstructed.

The regulatory considerations differ somewhat for generic and 505(b)(2) programs, where PLGA reverse engineering for ANDA submissions and PLGA polymer sameness for ANDA demonstrations become the central regulatory question rather than novel CMC characterization. PLGA polymer characterization for generics and working with an experienced PLGA reverse engineering CRO both matter here, since matching a reference listed drug’s polymer composition and microstructure requires many of the same analytical techniques used in this case study, applied in reverse. Marketed depot products such as Lupron Depot have been widely studied from this angle — see this PLGA characterization work on Lupron Depot and this related PLGA case study on reverse engineering the polymer in Lupron Depot — and the formulation challenges specific to leuprolide depot products offer useful points of comparison to the antipsychotic program described here. Other related case studies worth reviewing include PLGA characterization for a dexamethasone implant, goserelin PLGA implant characterization, and an exenatide PLGA microsphere case study on peptide-polymer interaction challenges, each of which illustrates a different facet of the polymer/process/analytical interplay described throughout this article.

10: What Are the Key Takeaways for Formulators Working on 3-Month Depot Antipsychotics?

The key takeaway is that successful PLGA microsphere formulation development for a 90-day antipsychotic depends on treating polymer selection, process parameters, sterilization strategy, and analytical characterization as one interconnected system rather than separate development streams handled in isolation. A polymer blend chosen without matching process controls, or a process optimized without a validated IVR method to confirm the result, is unlikely to deliver a reproducible 3-month release profile on the first attempt.

Practical lessons from this case study include:

• Blending PLGA grades can fine-tune release duration more precisely than relying on a single commercial grade, particularly for intermediate targets like 90 days that fall between common single-grade degradation windows.
• Encapsulation efficiency problems often trace back to aqueous-phase drug solubility, not the polymer itself — pH and phase-ratio adjustments can resolve issues that might otherwise be mistakenly attributed to the API-polymer interaction.
• Stirring speed and other process parameters deserve CPP-level attention early, since particle size drives both burst release and injectability, and is easy to underweight relative to polymer selection.
• Sterilization method should be locked early, since both terminal heat and gamma irradiation can measurably alter PLGA molecular weight and therefore release duration.
• Accelerated IVR testing is valuable for early screening but must be cross-validated against real-time data before a formulation is locked, since compressed timelines can behave differently from true physiological conditions in edge cases.
• A layered analytical package (GPC/SEC, particle sizing, HPLC, DSC, SEM, residual solvent and moisture testing) is necessary to explain why a formulation performs the way it does, not just confirm that it does — and that explanatory depth is often what separates a formulation ready for IND-enabling studies from one that still carries unresolved risk.

Conclusion:

This case study demonstrates that PLGA microsphere formulation development for a 3-month depot antipsychotic is achievable with a disciplined, data-driven approach that ties polymer science, process engineering, sterilization strategy, stability, and analytical characterization together from the earliest stages of development rather than treating them as sequential handoffs. The formulation ultimately achieved encapsulation efficiency above 85% and a near-zero-order 90-day release profile, with the three-phase burst/lag/erosion pattern confirmed through parallel real-time and accelerated IVR testing and structured to support a future IVIVC — outcomes that depended as much on rigorous analytical support as on the underlying formulation chemistry.

For sponsors developing long-acting injectables, partnering with a laboratory that offers dedicated PLGA formulation development services — with hands-on experience across PLGA characterization, particle size analysis, sterility and residual solvent testing, and biorelevant release testing — can materially shorten the path from early formulation screening to an IND-ready data package, and can help catch problems like encapsulation efficiency loss or burst-release variability before they become costly late-stage surprises.

Frequently Asked Questions:

Get In Touch With Us

Reference

• Markowicz-Piasecka M, Kubisiak M, Asendrych-Wicik K, Kołodziejczyk M, Grzelińska J, Fabijańska M, Pietrzak T. Long-acting injectable antipsychotics—a review on formulation and in vitro dissolution. Pharmaceutics. 2023 Dec 24;16(1):28.https://www.mdpi.com/1999-4923/16/1/28
• Chaurasia S, Mounika K, Bakshi V, Prasad V. 3-month parenteral PLGA microsphere formulations of risperidone: Fabrication, characterization and neuropharmacological assessments. Materials Science and Engineering: C. 2017 Jun 1;75:1496-505.https://www.sciencedirect.com/science/article/pii/S0928493116313613
• Yerragunta B, Jogala S, Chinnala KM, Aukunuru J. Development of a novel 3-month drug releasing risperidone microspheres. Journal of Pharmacy and Bioallied Sciences. 2015 Jan 1;7(1):37-44.https://journals.lww.com/jpbs/fulltext/2015/07010/Development_of_a_novel_3_month_drug_releasing.8.aspx
• Bellotti E, Contarini G, Geraci F, Torrisi SA, Piazza C, Drago F, Leggio GM, Papaleo F, Decuzzi P. Long-lasting rescue of schizophrenia-relevant cognitive impairments via risperidone-loaded microPlates. Drug Delivery and Translational Research. 2022 Aug;12(8):1829-42.https://link.springer.com/article/10.1007/s13346-021-01099-x
• Mohammadpour F, Kamali H, Hadizadeh F, Bagheri M, Shiadeh SN, Nazari A, Oroojalian F, Khodaverdi E. The PLGA microspheres synthesized by a thermosensitive hydrogel emulsifier for sustained release of risperidone. Journal of Pharmaceutical Innovation. 2022 Sep;17(3):712-24.https://link.springer.com/article/10.1007/s12247-021-09544-7
• Shah JC, Hong J. Model for long acting injectables (depot formulation) based on pharmacokinetics and physical chemical properties. The AAPS Journal. 2022 Mar 16;24(3):44.https://link.springer.com/article/10.1208/s12248-022-00695-0

About the Author

Priyal Darji